Sanfelice Raquel Arruda, Machado Laís Fernanda, Bosqui Larissa Rodrigues, Miranda-Sapla Milena Menegazzo, Tomiotto-Pellissier Fernanda, de Alcântara Dalevedo Gabriela, Ioris Dielle, Reis Guilherme Fonseca, Panagio Luciano Aparecido, Navarro Italmar Teodorico, Bordignon Juliano, Conchon-Costa Ivete, Pavanelli Wander Rogério, Almeida Ricardo Sergio, Costa Idessania Nazareth
Laboratório de Protozoologia Experimental - Departamento de Ciências Patológicas, Universidade Estadual de Londrina, Paraná CEP 86051-990, Brazil.
Laboratório de Micologia Médica e Microbiologia Bucal - Departamento de Microbiologia, Universidade Estadual de Londrina, Paraná, CEP 86057-970, Brazil.
Exp Parasitol. 2017 Oct;181:75-81. doi: 10.1016/j.exppara.2017.07.009. Epub 2017 Aug 1.
Due to the toxicity of conventional medication in toxoplasmosis, some drugs are being studied for treating this infection, such as statins, especially rosuvastatin compound, which is efficient in inhibiting the initial isoprenoid biosynthesis processes in humans and the parasite. The goal of this study was to assess the activity of rosuvastatin in HeLa cells infected with the RH strain of T. gondii. In the experiment, HeLa cells (1 × 10) were infected with tachyzoites of T. gondii (5 × 10). After the experimental infection, we assessed the number of infected cells and the amount of intracellular tachyzoites. In addition, culture supernatants were collected to determine the amount of cytokines by cytometric bead array. We observed that there was no cytotoxicity in the concentrations tested in this cell line. The effect of rosuvastatin showed a significant reduction in both the number of infected cells and the proliferation index of the intracellular parasite, when compared with the conventional treatment combining sulfadiazine and pyrimethamine for toxoplasmosis. There were also reduced levels of cytokines IL-6 and IL-17. Therefore, it was concluded that rosuvastatin exhibited antiproliferative activity. The data presented are significant to promote further studies and the search for alternative treatment for toxoplasmosis.
由于传统药物治疗弓形虫病存在毒性，一些药物正在被研究用于治疗这种感染，如他汀类药物，尤其是瑞舒伐他汀化合物，它在抑制人类和寄生虫的初始类异戊二烯生物合成过程中具有高效性。本研究的目的是评估瑞舒伐他汀对感染刚地弓形虫RH株的HeLa细胞的活性。在实验中，将HeLa细胞（1×10）用刚地弓形虫速殖子（5×10）感染。实验感染后，我们评估了感染细胞的数量和细胞内速殖子的数量。此外，收集培养上清液，通过细胞计数珠阵列测定细胞因子的量。我们观察到在该细胞系中测试的浓度下没有细胞毒性。与用于弓形虫病的磺胺嘧啶和乙胺嘧啶联合传统治疗相比，瑞舒伐他汀的作用显示感染细胞数量和细胞内寄生虫增殖指数均显著降低。细胞因子IL-6和IL-17的水平也有所降低。因此，得出结论瑞舒伐他汀具有抗增殖活性。所呈现的数据对于促进进一步研究和寻找弓形虫病的替代治疗方法具有重要意义。
